IF 2

Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-07 DOI: 10.1002/npr2.12499

Shinichiro Ochi, Takashi Tsuboi, Naomi Hasegawa, Hikaru Hori, Kayo Ichihashi, Yayoi Imamura, Tsuyoshi Okada, Fumitoshi Kodaka, Yoshitaka Saito, Jun-Ichi Iga, Toshiaki Onitsuka, Kiyokazu Atake, Shu-Ichi Ueno, Ryota Hashimoto, Norio Yasui-Furukori

{"title":"The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment.","authors":"Shinichiro Ochi, Takashi Tsuboi, Naomi Hasegawa, Hikaru Hori, Kayo Ichihashi, Yayoi Imamura, Tsuyoshi Okada, Fumitoshi Kodaka, Yoshitaka Saito, Jun-Ichi Iga, Toshiaki Onitsuka, Kiyokazu Atake, Shu-Ichi Ueno, Ryota Hashimoto, Norio Yasui-Furukori","doi":"10.1002/npr2.12499","DOIUrl":"10.1002/npr2.12499","url":null,"abstract":"Aim: Constipation is one of the most common adverse effects in schizophrenia treatment, and it can sometimes cause severe gastrointestinal disease. However, the results of association studies between constipation and psychotropic medications in patients with schizophrenia are inconsistent. Therefore, we investigated the characteristics of psychotropic and laxative prescriptions at discharge in patients with schizophrenia to clarify the association between psychotropics and constipation.Methods: We analyzed the data of 139 patients with schizophrenia with or without laxative prescriptions at discharge from eight institutions in 2020.Results: Sixty-two patients were prescribed laxatives at discharge. The prescription of benzodiazepines in the laxative use group (66.1%) was significantly higher than that in the non-laxative use group (39.0%) (p = 1.4 × 10-3), and the mean number of benzodiazepines in the laxative use group (1.2 ± 1.1/day) was significantly higher than that in the non-laxative use group (0.7 ± 0.9/day) (p = 2.6 × 10-3). Multivariate logistic regression analyses revealed that benzodiazepine prescriptions were significantly associated with laxative usage (odds ratio, 3.059; 95% confidence interval, 1.523-6.144; p = 2.0 × 10-3).Conclusion: Benzodiazepines may be associated with constipation in patients with schizophrenia. Therefore, clinicians should be cautious when prescribing benzodiazepines for the treatment of schizophrenia.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12499"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development. 新南威尔士州大麻药物咨询服务回顾性查询分析，为临床指导资源开发提供信息。

IF 2

Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-17 DOI: 10.1002/npr2.12498

Myfanwy Graham, Edward Eden, Kelsey Maddison, Luise Lago, Samuel Allingham, Catherine J Lucas, Jennifer Schneider, Jennifer H Martin

{"title":"NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development.","authors":"Myfanwy Graham, Edward Eden, Kelsey Maddison, Luise Lago, Samuel Allingham, Catherine J Lucas, Jennifer Schneider, Jennifer H Martin","doi":"10.1002/npr2.12498","DOIUrl":"10.1002/npr2.12498","url":null,"abstract":"Background: An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS.Methods: A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.Results: Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10-90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients.Conclusion: The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12498"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 3

Medical Gas Research Pub Date : 2025-03-01 Epub Date: 2024-09-25 DOI: 10.4103/mgr.MEDGASRES-D-24-00047

Gerardo Tricarico, Mauro Poggialini, Valter Travagli

引用次数: 0

New approach of modern pharmacology: from gasotransmitters to traditional mineral drugs. 现代药理学的新方法：从气体递质到传统矿物药。

IF 3

Medical Gas Research Pub Date : 2025-03-01 Epub Date: 2024-06-26 DOI: 10.4103/mgr.MEDGASRES-D-24-00022

Yefan Duan, Jianfei Sun

引用次数: 0

Warm alkaline hydrogen peroxide solution as an oxygen-releasing antihypoxic drug: potential benefits and applications. 温碱性过氧化氢溶液作为一种释放氧气的抗缺氧药物：潜在的益处和应用。

IF 3

Medical Gas Research Pub Date : 2025-03-01 Epub Date: 2024-10-02 DOI: 10.4103/mgr.MEDGASRES-D-24-00058

Anatoly N Osipov, Natalya A Urakova, Aleksandr L Urakov, Petr D Shabanov

引用次数: 0

Hydrogen sulfide: an emerging gasotransmitter involved in the survival of pancreatic islets during diabetes therapy. 硫化氢：糖尿病治疗过程中与胰岛存活有关的一种新兴气体递质。

IF 3

Medical Gas Research Pub Date : 2025-03-01 Epub Date: 2024-10-02 DOI: 10.4103/mgr.MEDGASRES-D-24-00067

Udayakumar Karunakaran

引用次数: 0

Current status and features of antipsychotic prescriptions in Japanese forensic psychiatric wards based on a forensic inpatient database. 基于法医住院病人数据库的日本法医精神病病房抗精神病药物处方的现状和特点。

IF 2

Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-26 DOI: 10.1002/npr2.12505

Koji Takeda, Hiroko Kashiwagi, Keisuke Takanobu, Ryotaro Kubota, Ryo Naoe, Yuji Yamada, Junko Koike, Toshiaki Kono, Yuki Kako, Naotsugu Hirabayasi

{"title":"Current status and features of antipsychotic prescriptions in Japanese forensic psychiatric wards based on a forensic inpatient database.","authors":"Koji Takeda, Hiroko Kashiwagi, Keisuke Takanobu, Ryotaro Kubota, Ryo Naoe, Yuji Yamada, Junko Koike, Toshiaki Kono, Yuki Kako, Naotsugu Hirabayasi","doi":"10.1002/npr2.12505","DOIUrl":"10.1002/npr2.12505","url":null,"abstract":"Aim: Psychopharmacotherapy plays an important role in the treatment of mentally disordered offenders (MDOs) with schizophrenia spectrum disorders. However, there have been few large-scale reports from multiple forensic psychiatric wards. This study aimed to clarify the current state of antipsychotic medications for MDOs with schizophrenia spectrum disorders in Japanese forensic psychiatric wards.Methods: Medical information, including age, sex, psychiatric diagnosis, index offense, seclusion or restraint experience during hospitalization, and medication for patients discharged from 32 forensic wards nationwide between September 1, 2019 and December 31, 2021 was provided by the Database Scientific Utilization Project of Japanese forensic psychiatric wards. We analyzed the data of MDOs with schizophrenia spectrum disorders who were prescribed psychotropic medications at the time of discharge, especially focusing on comparing differences between the three groups (clozapine, long-acting injection (LAI), and other medications).Results: A total of 362 MDOs with schizophrenia spectrum disorders were prescribed psychotropic medications at discharge. The prescription rates of clozapine and LAI were 23.2% and 24.9%, respectively. Additionally, the rate of antipsychotic polypharmacy was 37.8%. Among the three groups, the clozapine group had the highest rate of seclusion experience (46.4%), a long mean length of hospitalization (1758 days), and the lowest rate of antipsychotic polypharmacy (4.8%). Olanzapine was the most commonly prescribed antipsychotic medication.Conclusion: This study revealed the current state of antipsychotic medications for MDOs admitted to forensic psychiatric wards in Japan. Future studies are needed to clarify the relevance of antipsychotic medications in the prognosis of MDOs.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12505"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Orexin concentrations and diurnal variation in the cerebrospinal fluid of intensive care unit patients undergoing aortic surgery with spinal drainage. 接受主动脉手术并进行脊髓引流的重症监护室患者脑脊液中的奥利司他浓度和昼夜变化。

IF 2

Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-14 DOI: 10.1002/npr2.12504

Seiya Nishiyama, Akiko Sekine, Tomoyuki Masuyama, Kanae Nagatomo, Takashi Kanbayashi, Masamitsu Sanui

{"title":"Orexin concentrations and diurnal variation in the cerebrospinal fluid of intensive care unit patients undergoing aortic surgery with spinal drainage.","authors":"Seiya Nishiyama, Akiko Sekine, Tomoyuki Masuyama, Kanae Nagatomo, Takashi Kanbayashi, Masamitsu Sanui","doi":"10.1002/npr2.12504","DOIUrl":"10.1002/npr2.12504","url":null,"abstract":"Background: Cerebrospinal fluid (CSF) levels of orexin show a cyclic diurnal variation in healthy subjects, which is diminished in patients with certain diseases. However, possible circadian variations in orexin levels in critically ill patients remain unknown. In this study, we evaluated the orexin concentrations in the CSF and their diurnal variation in patients undergoing thoracic aortic aneurysm repair with lumbar intrathecal catheterization for CSF drainage after non-neurosurgery.Methods: Eligible patients with a lumbar intrathecal catheter placed for CSF drainage following aortic surgery at a single-center ICU between September 2019 and February 2020 were included. Catheters were placed before anesthesia induction, and CSF was collected at the time of catheter placement, ICU admission, and daily at 6:00, 12:00, 18:00, and 24:00 until the catheter was removed or for up to 5 days after admission to the ICU.Results: Three patients (Patients A, B, and C) who underwent thoracic aortic aneurysm repair were included. Patients B and C received sedatives or hypnotics during the orexin measurement period. The baseline orexin levels for Patients A, B, and C were 219.9, 312.3, and 403.8 pg/mL, while the mean orexin levels were 319.4 ± 82.6, 372.4 ± 56.0, and 306.3 ± 48.3 pg/mL, respectively. For all three patients, orexin levels showed diurnal variations, but no consistent periodic changes.Conclusion: CSF orexin concentrations for patients undergoing thoracic aortic aneurysm repair in the ICU were within the reported range compared to those of previously reported healthy subjects; however, consistent periodic diurnal variations were not observed.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12504"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative study on the anti-inflammatory and protective effects of different oxygen therapy regimens on lipopolysaccharide-induced acute lung injury in mice. 不同氧疗方案对脂多糖诱发的小鼠急性肺损伤的抗炎和保护作用的比较研究。

IF 3

Medical Gas Research Pub Date : 2025-03-01 Epub Date: 2024-09-25 DOI: 10.4103/mgr.MEDGASRES-D-24-00044

Xinhe Wu, Yanan Shao, Yongmei Chen, Wei Zhang, Shirong Dai, Yajun Wu, Xiaoge Jiang, Xinjian Song, Hao Shen

{"title":"Comparative study on the anti-inflammatory and protective effects of different oxygen therapy regimens on lipopolysaccharide-induced acute lung injury in mice.","authors":"Xinhe Wu, Yanan Shao, Yongmei Chen, Wei Zhang, Shirong Dai, Yajun Wu, Xiaoge Jiang, Xinjian Song, Hao Shen","doi":"10.4103/mgr.MEDGASRES-D-24-00044","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00044","url":null,"abstract":"Oxygen therapy after acute lung injury can regulate the inflammatory response and reduce lung tissue injury. However, the optimal exposure pressure, duration, and frequency of oxygen therapy for acute lung injury remain unclear. In the present study, after intraperitoneal injection of lipopolysaccharide in ICR mice, 1.0 atmosphere absolute (ATA) pure oxygen and 2.0 ATA hyperbaric oxygen treatment for 1 hour decreased the levels of proinflammatory factors (interleukin-1beta and interleukin-6) in peripheral blood and lung tissues. However, only 2.0 ATA hyperbaric oxygen increased the mRNA levels of anti-inflammatory factors (interleukin-10 and arginase-1) in lung tissue; 3.0 ATA hyperbaric oxygen treatment had no significant effect. We also observed that at 2.0 ATA, the anti-inflammatory effect of a single exposure to hyperbaric oxygen for 3 hours was greater than that of a single exposure to hyperbaric oxygen for 1 hour. The protective effect of two exposures for 1.5 hours was similar to that of a single exposure for 3 hours. These results suggest that hyperbaric oxygen alleviates lipopolysaccharide-induced acute lung injury by regulating the expression of inflammatory factors in an acute lung injury model and that appropriately increasing the duration and frequency of hyperbaric oxygen exposure has a better tissue-protective effect on lipopolysaccharide-induced acute lung injury. These results could guide the development of more effective oxygen therapy regimens for acute lung injury patients.","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":" ","pages":"171-179"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular hydrogen gas and its therapeutic potential in recent disease progression. 分子氢气及其在近期疾病进展中的治疗潜力。

IF 3

Medical Gas Research Pub Date : 2025-03-01 Epub Date: 2024-09-25 DOI: 10.4103/mgr.MEDGASRES-D-24-00012

Md Habibur Rahman, Cheol-Su Kim, Kyu-Jae Lee

引用次数: 0

其他最新文献